Poster Discussion

Co-Chair(s)

• 

  Hartmut Goldschmidt, MD (he/him/his)

  Head of the GMMG Study Group
  Internal Medicine V, GMMG Study Group at University Hospital Heidelberg, Heidelberg, Germany
  Heidelberg, Baden-Wurttemberg, Germany
• 

  Simon Harrison, MBBS, MRCP(uk), FRCPath(uk), FRACP, PhD (he/him/his)

  Director, Centre of Excellence in Cellular Immunotherapy
  Peter MacCallum Cancer Centre
  Melbourne, Australia

Presentations:

• 12:00 - 12:02 East Coast USA Time

  Introduction
• 12:02 - 12:08 East Coast USA Time

  (PA-324) AKR1B1/NAT10 Mediate IL4I1 ac4C Modification to Regulate Tryptophan Metabolism and Promote Multiple Myeloma Proliferation
  

  Abstract Presenter: Rongfang Wei, PhD – Department of Hematology, The Eighth Affiliated Hospital, Sun Yat-sen University
• 12:08 - 12:14 East Coast USA Time

  (PA-039) Differential Impact of BCMA (TNFRSF17) Extracellular Domain Mutations on in vitro Potency of Elranatamab versus Teclistamab
  

  Abstract Presenter: Maria Josic, MS – Pfizer
• 12:14 - 12:20 East Coast USA Time

  (PA-094) Early Mortality Associated with Real-World Bispecific Antibody Therapy for Relapsed/Refractory Multiple Myeloma
  

  Abstract Presenter: Carlyn Rose Tan, MD (she/her/hers) – Memorial Sloan Kettering Cancer Center
• 12:20 - 12:26 East Coast USA Time

  (PA-307) Iberdomide (Iber) Treatment (Tx) Enhances Manufactured Chimeric Antigen Receptor (Car) T Cell Expansion And Functionality And Is Immunostimulatory In Patients Post-Car T Cell Therapy
  

  Abstract Presenter: Michael D. Amatangelo, PhD – Bristol Myers Squibb, Summit, NJ, USA
• 12:26 - 12:32 East Coast USA Time

  (PA-374) MGUS Prevalence from a Large-Scale Community Study from Rural India (IMAGe-002B Study)
  

  Abstract Presenter: Uday Yanamandra, MD (DM) – AFMC , Pune
• 12:32 - 12:38 East Coast USA Time

  (PA-255) Multi-hit Cytogenetics Risk Events Associated with IFN-I Suppression across TME of NDMM Patients and Poor Outcomes
  

  Abstract Presenter: William C. Pilcher, Jr., BsC (he/him/his) – Emory University
• 12:38 - 12:44 East Coast USA Time

  (PA-180) Revealing Clonal Evolution and Assessing Immune Reconstitution in Multiple Myeloma Using Next-Generation Sequencing-Based Minimal Residual Disease (NGS-MRD) Analysis
  

  Abstract Presenter: Yuntong Liu, liuyuntong@ihcam.ac.cn – Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
• 12:44 - 12:50 East Coast USA Time

  (PA-529) Risk of Infections after Bispecific Antibodies Targeting Anti-B-cell Maturation Antigen (BCMA) in Multiple Myeloma-intravenous Immunoglobulin (IVIG) Significantly Lowers the Risk of Infection
  

  Abstract Presenter: Amandeep Godara, MD – University of Utah